Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have received an average recommendation of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $8.20.

A number of research firms recently issued reports on WHWK. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Leerink Partners began coverage on shares of Whitehawk Therapeutics in a research report on Monday, July 13th. They issued an “outperform” rating and a $9.00 price objective for the company. B. Riley Financial began coverage on shares of Whitehawk Therapeutics in a research note on Thursday, June 25th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Wall Street Zen upgraded shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th.

Whitehawk Therapeutics Stock Up 2.9%

Shares of Whitehawk Therapeutics stock opened at $4.20 on Friday. The stock has a market capitalization of $239.44 million, a P/E ratio of -3.75 and a beta of 0.81. Whitehawk Therapeutics has a 12-month low of $1.82 and a 12-month high of $5.49. The company has a 50-day simple moving average of $4.30 and a 200 day simple moving average of $4.13.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. On average, equities analysts anticipate that Whitehawk Therapeutics will post -1.1 earnings per share for the current year.

Institutional Trading of Whitehawk Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Montanova Capital LLC lifted its position in Whitehawk Therapeutics by 16.2% during the 2nd quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock valued at $19,694,000 after purchasing an additional 600,000 shares during the period. Two Sigma Securities LLC acquired a new stake in Whitehawk Therapeutics during the 2nd quarter worth $46,000. Bank of America Corp DE bought a new position in shares of Whitehawk Therapeutics in the 2nd quarter worth $159,000. ADAR1 Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics during the second quarter worth $6,144,000. Finally, BlackRock Inc. acquired a new stake in shares of Whitehawk Therapeutics during the second quarter worth $8,807,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Whitehawk Therapeutics (NASDAQ: WHWK) is a clinical-stage biopharmaceutical company focused on developing new medicines for cancer. Its research is centered on antibody-drug conjugates, which are designed to use targeted antibodies to deliver cancer-killing agents directly to tumor cells.

The company is advancing a pipeline of oncology therapies intended to address cancers with significant unmet medical needs. Its activities include drug discovery, preclinical research and clinical development, with programs designed to evaluate the safety and potential effectiveness of its targeted therapeutic candidates.

Whitehawk Therapeutics is an early-stage biotechnology company, and its pipeline remains subject to the clinical, regulatory and commercialization risks associated with developing experimental medicines.